Singapore consults on major revisions to drug registration procedures
This article was originally published in SRA
Singapore's Health Sciences Authority has proposed substantial changes to its guidance on the registration of human medicinal products to incorporate, among other things, a new chapter on the registration of biosimilar products and a new fast-track procedure for evaluating generic drug applications1,2.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.